Target
Vascular Endothelial Growth Factor (VEGF)
20 abstracts
Abstract
International, open-label phase 2 study of regorafenib plus pembrolizumab in patients with advanced hepatocellular carcinoma (HCC) previously treated with immune checkpoint inhibitors (ICI).Org: Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, CA, Los Angeles, CA, Seoul National University Hospital, Seoul, South Korea,
Abstract
Real-world biomarker testing, treatment patterns and outcomes in a US cohort of patients with advanced ovarian cancer.Org: AstraZeneca Pharmaceuticals LP,
Abstract
Phase 2 randomized study evaluating safety, efficacy, and optimal dose of ABBV-400 in combination with fluorouracil, folinic acid, and bevacizumab in previously treated patients with metastatic colorectal cancer.Org: The University of Texas MD Anderson Cancer Center, Stem Cell Transplantation Rsch, Houston, TX, Hadassah Medical Center, City of Hope Comprehensive Cancer Center, AbbVie Inc., North Chicago, IL, Duke University School of Medicine, Department of Head and Neck Surgery & Communication Sciences, Durham, NC,
Abstract
Hepatic artery infusion chemotherapy combined with immune checkpoint inhibitors and tyrosine kinase inhibitors for advanced hepatocellular carcinoma with portal vein tumor thrombus: A single center retrospective study.Org: Department II of Interventional Radiology,
Abstract
The BEV1L study: Do real-world outcomes associated with the addition of bevacizumab to first-line chemotherapy in patients with ovarian cancer reinforce clinical trial findings?Org: GSK, Flatiron Health, San Francisco, CA,
Abstract
Stereotactic body radiation therapy combined with atezolizumab and bevacizumab for hepatocellular carcinoma with extrahepatic metastasis: Preliminary result of a single-arm study.Org: Fudan University Shanghai Cancer Center, Shanghai Henlius Biotech, China National Biotec Group,
Abstract
Reshaping the tumor microenvironment of cold soft-tissue sarcomas with anti-VEGFR targeted therapy: A Phase 2 Trial of Regorafenib combined with avelumab.Org: ImmuSmol,
Abstract
Efficacy and safety of regorafenib combined with PD-1 inhibitors in patients with advanced hepatocellular beyond atezolizumab plus bevacizumab: A retrospective analysis of real-world evidence.Org: The PLA 307 Clinical College of Anhui Medical University, The Fifth Clinical Medical College of Anhui Medical University, Institute of Molecular Medicine (IMM),
Abstract
The treatment outcomes of patients who failed to be randomly assigned after atezo/bev induction therapy in the Chinese TALENTop study.Org: Key Laboratory of Carcinogenesis and Cancer Invasion of Ministry of Education, Department Of Hepatic Surgery, Shanghai Eastern Hepatobiliary Surgery Hospital, SYSUCC, Guangzhou, Tongji Hospital, Huazhong University of Science and Technology, Liver Cancer Center, Tianjin Medical University Cancer Institute & Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin; Tianjin’s Clinical Research Center for Cancer,
Abstract
NeoRAS wild-type metastatic colorectal cancer in the SCRUM-Japan GOZILA study.Org: Department of Gastroenterological Chemotherapy, Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan, Department of Gastroenterology and Gastrointestinal Oncology, National Cancer Center Hospital East, Kashiwa, Japan, Kobe City Medical Center General Hospital, Kobe, Hyogo, Japan, Department of Medical Oncology, Kochi Medical School, Nankoku-City, Japan, Department of Gastroenterology and Hepatology, Hokkaido University Hospital, Hokkaido, Japan,
Abstract
The impact of renin-angiotensin-aldosterone system inhibitors on immune checkpoint inhibitor-associated adverse cardiovascular events.Org: National Taiwan University Hospital Yunlin Branch, Mount Auburn Hospital, Harvard Medical School, Cambridge University Hospitals NHS Foundation Trust, Taipei TzuChi Hospital,
Abstract
Phase I/II study of dianhydrogalactitol in patients with recurrent malignant glioma.Org: Tennessee Oncology, PLLC, Sarah Cannon Research Institute/Florida Cancer Specialists, University of California Irvine, Del Mar Pharmaceuticals, Sarah Cannon Research Institute/Tennessee Oncology,
Abstract
Real-world treatment patterns and outcomes by mismatch repair/microsatellite instability (MMR/MSI) status in patients (pts) with advanced endometrial cancer (aEC), 2018-2023.Org: Flatiron Health, Inc.,
Abstract
FDA analysis of treatment efficacy based on etiology of hepatocellular carcinoma.Org: US Food and Drug Administration, Silver Spring, MD, FDA/CDER, Center for Drug Evaluation and Research, U.S. Food and Drug Administration,
Abstract
NRG-GU012: Randomized phase II stereotactic ablative radiation therapy (SABR) for patients with metastatic unresected renal cell carcinoma (RCC) receiving immunotherapy (SAMURAI).Org: Medical College of Wisconsin, NRG Oncology Statistics and Data Management Center, American College of Radiology, Philadelphia, PA, Dana-Farber Cancer Institute, Harvard Medical School, University Hospitals Seidman Cancer Center,
Abstract
CABIOS trial: A phase Ib study of cabozantinib and nivolumab in combination with abiraterone in patients (pts) with metastatic hormone sensitive prostate cancer (mHSPC).Org: Washington University School of Medicine in St Louis, Saint Lukes Hospital,
Abstract
Frequency of KRAS, NRAS, and BRAF mutations in colorectal cancer in an Argentinian population.Org: Medical Affairs Department, Merck S.A., Biomakers SA,
Abstract
Characteristics and outcomes of 795 patients with renal cell cancer following hospitalization for acute myocardial infarction.Org: Raj Multispeciality Hospital, LSU Health Shreveport, Danbury Hospital, Louisiana State University Shreveport, Kamineni Academy of Medical Sciences and Research Centre, Hyderabad, India,
Abstract
Introducing yttrium-90 radioembolization to atezolizumab and bevacizumab regimen for intermediate and advanced stage hepatocellular carcinoma: A preliminary report of safety and effectiveness.Org: University of Chicago Medical Center, Chicago, IL, Chicago, IL, Ascension Providence Hospital, Southfield, MI, University of Chicago,
Abstract
Oxaliplatin based chemotherapy for advanced well-differentiated neuroendocrine tumors: A systematic review and meta-analysis.Org: Department of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) “Dino Amadori”, Meldola, Italy, Italy, Qilu Hospital of Shandong University, Jinan, China National Biotec Group,